Logo image of NCNA

NUCANA PLC-ADR (NCNA) Stock Fundamental Analysis

NASDAQ:NCNA - Nasdaq - US67022C2052 - ADR - Currency: USD

1.09  +0.03 (+2.83%)

After market: 1.06 -0.03 (-2.75%)

Fundamental Rating

1

Overall NCNA gets a fundamental rating of 1 out of 10. We evaluated NCNA against 572 industry peers in the Biotechnology industry. NCNA may be in some trouble as it scores bad on both profitability and health. NCNA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NCNA has reported negative net income.
NCNA had a negative operating cash flow in the past year.
NCNA had negative earnings in each of the past 5 years.
In the past 5 years NCNA always reported negative operating cash flow.
NCNA Yearly Net Income VS EBIT VS OCF VS FCFNCNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -140.43%, NCNA is doing worse than 83.30% of the companies in the same industry.
The Return On Equity of NCNA (-741.68%) is worse than 82.59% of its industry peers.
Industry RankSector Rank
ROA -140.43%
ROE -741.68%
ROIC N/A
ROA(3y)-68.88%
ROA(5y)-53.12%
ROE(3y)-110.2%
ROE(5y)-79.05%
ROIC(3y)N/A
ROIC(5y)N/A
NCNA Yearly ROA, ROE, ROICNCNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NCNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NCNA Yearly Profit, Operating, Gross MarginsNCNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

NCNA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NCNA has more shares outstanding
Compared to 1 year ago, NCNA has a worse debt to assets ratio.
NCNA Yearly Shares OutstandingNCNA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M
NCNA Yearly Total Debt VS Total AssetsNCNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -15.22, we must say that NCNA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -15.22, NCNA is not doing good in the industry: 82.59% of the companies in the same industry are doing better.
NCNA has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of NCNA (0.04) is worse than 61.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -15.22
ROIC/WACCN/A
WACCN/A
NCNA Yearly LT Debt VS Equity VS FCFNCNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M 80M

2.3 Liquidity

NCNA has a Current Ratio of 1.08. This is a normal value and indicates that NCNA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.08, NCNA is doing worse than 87.74% of the companies in the same industry.
NCNA has a Quick Ratio of 1.08. This is a normal value and indicates that NCNA is financially healthy and should not expect problems in meeting its short term obligations.
NCNA has a worse Quick ratio (1.08) than 85.79% of its industry peers.
Industry RankSector Rank
Current Ratio 1.08
Quick Ratio 1.08
NCNA Yearly Current Assets VS Current LiabilitesNCNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

NCNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.34%, which is quite impressive.
EPS 1Y (TTM)31.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 24.95% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.3%
EPS Next 2Y19.49%
EPS Next 3Y23.99%
EPS Next 5Y24.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NCNA Yearly Revenue VS EstimatesNCNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 10M 20M 30M 40M 50M
NCNA Yearly EPS VS EstimatesNCNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 10 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NCNA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NCNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NCNA Price Earnings VS Forward Price EarningsNCNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NCNA Per share dataNCNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as NCNA's earnings are expected to grow with 23.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.49%
EPS Next 3Y23.99%

More info and screens

0

5. Dividend

5.1 Amount

NCNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUCANA PLC-ADR

NASDAQ:NCNA (2/21/2025, 8:00:01 PM)

After market: 1.06 -0.03 (-2.75%)

1.09

+0.03 (+2.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-25 2024-11-25/bmo
Earnings (Next)03-18 2025-03-18/amc
Inst Owners16.67%
Inst Owner Change-45.66%
Ins Owners0.3%
Ins Owner ChangeN/A
Market Cap2.47M
Analysts82.5
Price Target25.5 (2239.45%)
Short Float %2.37%
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-38.83%
Min EPS beat(2)-62.57%
Max EPS beat(2)-15.09%
EPS beat(4)0
Avg EPS beat(4)-34.67%
Min EPS beat(4)-62.57%
Max EPS beat(4)-15.09%
EPS beat(8)2
Avg EPS beat(8)-31.17%
EPS beat(12)5
Avg EPS beat(12)-15.61%
EPS beat(16)6
Avg EPS beat(16)-15.9%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.11%
PT rev (3m)11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.51
P/tB 1.23
EV/EBITDA N/A
EPS(TTM)-14.54
EYN/A
EPS(NY)-9.41
Fwd EYN/A
FCF(TTM)-9.86
FCFYN/A
OCF(TTM)-9.66
OCFYN/A
SpS0
BVpS2.12
TBVpS0.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -140.43%
ROE -741.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-68.88%
ROA(5y)-53.12%
ROE(3y)-110.2%
ROE(5y)-79.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.58%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.08
Quick Ratio 1.08
Altman-Z -15.22
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)88.98%
Cap/Depr(5y)125.19%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
EPS Next Y13.3%
EPS Next 2Y19.49%
EPS Next 3Y23.99%
EPS Next 5Y24.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.35%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.38%
OCF growth 3YN/A
OCF growth 5YN/A